CA Irvine의 전이성 암 임상 시험
전이성 암 관련 연구 16개가 Irvine 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
피험자 모집 중1상
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- City of Hope at Irvine Lennar, Irvine
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
피험자 모집 중1상
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
피험자 모집 중2/3상
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UCI Health - Irvine, Irvine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
피험자 모집 중3상
- City of Hope Lennar, Irvine
- Kaiser Permanente Zion Medical Center, Irvine
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
피험자 모집 중3상
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
피험자 모집 중3상
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
피험자 모집 중1상
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
피험자 모집 중1/2상
- City of Hope at Irvine Lennar, Irvine
- City of Hope Investigational Drug Services (IDS), Irvine
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
피험자 모집 중2상
- City of Hope at Irvine Lennar, Irvine
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
피험자 모집 중1/2상
- City of Hope - Orange County Lennar Foundation Cancer Center, Irvine
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
피험자 모집 중3상
- Hoag Hospital Center, Irvine
- Hoag Hospital Irvine, Irvine
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
피험자 모집 중1/2상
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
피험자 모집 중1상
- City of Hope - Lennar, Irvine
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Irvine
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
피험자 모집 중1상
- UC Irvine, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
피험자 모집 중1/2상
- University of California, Irvine, Irvine
다른 도시의 전이성 암 시험
- Houston, TX연구 104개
- New York City, NY연구 93개
- Nashville, TN연구 70개
- Boston, MA연구 63개
- Los Angeles, CA연구 57개
- St. Louis, MO연구 54개
- Arlington, VA연구 53개
- Philadelphia, PA연구 46개
- Chicago, IL연구 45개
- San Antonio, TX연구 44개
- Washington, DC연구 43개
- Dallas, TX연구 42개
Irvine의 다른 연구
- 비소세포폐암연구 25개
- 유방암연구 23개
- 암 (전체)연구 17개
- 폐암연구 15개
- 다발성 골수종연구 14개
- 전립선암연구 14개
- 난소암연구 12개
- 두경부 편평세포암연구 11개
- 방광암연구 11개
- 알츠하이머병연구 11개
- 대장직장암연구 10개
- 췌장암연구 10개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.